Back to discover
Disease

Plague

Late-stage therapeutic developmentEmerging research
MeSHPlague
1
Publications
8
Clinical trials
2008
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Plague: past, present, and future.

Research2008-01-01PLoS medicine

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials expected to report results, the earliest in Q1 2027.
  • 2 industry developments reported.
Upcoming Milestones
Clinical Milestones3View
Results posted 1
Results expected 2
Industry & Market2View
Activity timeline5

Clinical trials

6 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
8
All trials
2
Active
2
Late-stage
6
Completed
Recently completed

An Open-label, Randomised, Non-inferiority Trial of the Efficacy and Safety of Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin in the Treatment of Bubonic Plague

Phase 3 · Completed · University of Oxford

Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Phase 2 · Completed · Dynavax Technologies Corporation

Immunogenicity and Safety of Subunit Plague Vaccine Comprised by Fraction 1 Capsule (F1) and Virulence-Associated (V) Antigens: A Random Phase 2a Clinical Trial

Phase 2 · Completed · Jiangsu Province Centers for Disease Control and Prevention

A Randomized, Non-inferiority, Active Controlled Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin Versus Doxycycline in the Treatment of Plague in Humans

Phase 2 · Completed · Centers for Disease Control and Prevention

Safety and Efficacy of Gentamicin Versus Streptomycin for the Treatment of Naturally Occurring Human Plague and Evaluation of Rapid Diagnostic Test Kits for Yersinia Pestis

Phase 2/3 · Completed · Centers for Disease Control and Prevention

A Phase 1, Open-Label, Dose-Escalating Study to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant Plague Vaccine rF1V in Healthy Volunteers

Phase 1 · Completed · DynPort Vaccine Company LLC, A GDIT Company

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Plague: past, present, and future.

PLoS medicine · 2008 · 276 cites
Recent publications

Plague: past, present, and future.

PLoS medicine · 2008 · 276 cites
Leading journals1
  • PLoS medicine1
Leading researchers8
  • Atshabar BB1
  • Begon M1
  • Belmain SR1
  • Bertherat E1
  • Carniel E1
  • Gage KL1
  • Leirs H1
  • Rahalison L1
Affiliations (unnormalised)1
  • Centre for Ecological and Evolutionary Synthesis1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.

Identifiers
MeSHPlague
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.